Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
AI stocks stumble amid growing safety fears
Warnings from Anthropic, OpenAI, and SpaceX are raising questions over the future of the AI buildout.
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.30 | 20.40 | 0.23% |
| CAC 40 | 8,186.93 | 0.00 | 0.00% |
| DAX 40 | 25,716.71 | 178.96 | 0.70% |
| Dow JONES (US) | 51,778.04 | 316.14 | 0.61% |
| FTSE 100 | 10,816.14 | 127.67 | 1.19% |
| HKSE | 24,803.56 | 199.27 | 0.81% |
| NASDAQ | 26,418.30 | 439.87 | 1.69% |
| Nikkei 225 | 64,461.13 | 324.88 | 0.51% |
| NZX 50 Index | 13,663.55 | 93.04 | -0.68% |
| S&P 500 | 7,637.76 | 85.95 | 1.14% |
| S&P/ASX 200 | 8,744.00 | 11.60 | 0.13% |
| SSE Composite Index | 3,900.08 | 24.47 | 0.63% |